{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:56Z","timestamp":1784095496814,"version":"3.55.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1K23AI165290"],"award-info":[{"award-number":["1K23AI165290"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Long-acting cabotegravir\/rilpivirine (LA-CAB\/RPV) was approved for use in virally suppressed patients with human immunodeficiency virus (HIV) in January 2021. While this was a paradigm shift for many patients living with HIV, as LA-CAB\/RPV was the first injectable complete regimen for the treatment of HIV, several patient populations, including those lacking virologic suppression, have not been able to easily access this advance in science and care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>In this article, we provide an update on 2 patients from our previous report and describe one further patient who experienced treatment failure following initiation of LA-CAB\/RPV. Additionally, we review reports published to date of the clinical outcomes of patients with viremia who have accessed LA-CAB\/RPV in the setting of baseline resistance-associated mutations (RAMs) to either component and any resulting RAMs at virologic failure. On the basis of this evidence, we recommend that hybrid or all-injectable regimens be considered for patients who have struggled with adherence to oral antiretroviral therapy or have partial or full resistance to one component of LA-CAB\/RPV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The case series reported here adds to literature supporting the notion that LA-CAB\/RPV can be successfully used in patients who are viremic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae216","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T01:03:03Z","timestamp":1721437383000},"page":"1136-1141","source":"Crossref","is-referenced-by-count":1,"title":["Strategic use of salvage long-acting antiretrovirals in the setting of resistance"],"prefix":"10.1093","volume":"81","author":[{"given":"Christin","family":"Kilcrease","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Johns Hopkins Hospital , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Agwu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, and Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel D","family":"Weld","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, and Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"1","key":"2026071501215771400_CIT0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12981-022-00477-w","article-title":"Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series","volume":"19","author":"Kilcrease","year":"2022","journal-title":"AIDS Res Ther"},{"issue":"10","key":"2026071501215771400_CIT0002","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2026071501215771400_CIT0003","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026071501215771400_CIT0004","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting injectable cabotegravir\/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy","volume":"78","author":"Brock","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2026071501215771400_CIT0005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/QAD.0000000000003273","article-title":"Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient","volume":"36","author":"Barnett","year":"2022","journal-title":"AIDS"},{"issue":"2","key":"2026071501215771400_CIT0006","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/hiv.13370","article-title":"Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy","volume":"24","author":"D\u2019Amico","year":"2023","journal-title":"HIV Med"},{"key":"2026071501215771400_CIT0007","year":"2022"},{"key":"2026071501215771400_CIT0008","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2023"},{"issue":"4","key":"2026071501215771400_CIT0009","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14787210.2021.1829473","article-title":"Adolescents and young adults with early acquired HIV infection in the Unites States: unique challenges in treatment and secondary prevention","volume":"19","author":"Yusuf","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"2026071501215771400_CIT0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026071501215771400_CIT0011","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.lanepe.2023.100793","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland","volume":"36","author":"Thoueille","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"19","key":"2026071501215771400_CIT0012","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug resistant HIV-1 infection","volume":"386","author":"Maurer-Segal","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071501215771400_CIT0013","year":"2022"},{"issue":"9","key":"2026071501215771400_CIT0014","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"issue":"4","key":"2026071501215771400_CIT0015","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2022","journal-title":"Top Antivir Med"},{"issue":"2","key":"2026071501215771400_CIT0016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society\u2013USA panel","volume":"68","author":"Gunthard","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2026071501215771400_CIT0017","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae216\/58797552\/zxae216.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/22\/1136\/60500458\/zxae216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/22\/1136\/60500458\/zxae216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:22:07Z","timestamp":1784092927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/22\/1136\/7719021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":17,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,11,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae216","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,15]]},"published":{"date-parts":[[2024,7,24]]}}}